CardioKinetix, a medical device company, has secured $44 million in a two-tranche series E venture capital financing. The investment round was led by new investors SV Life Sciences and New Leaf Venture Partners. Previous investors, including U.S. Venture Partners and JPMorgan Partners, also participated.
Paul LaViolette, partner at SV Life Sciences, and Jeani Delagardelle, managing director at New Leaf Venture Partners, will join CardioKinetix’s board of directors. The financing will be used for the development of the Parachute device, including conducting clinical studies to further support the initial commercialization of Parachute in Europe and a PMA submission to FDA.
Click here for the release from Market Wire.